摩根大通发表报告指，近日与百济神州(06160.HK) (ONC.US) 管理层交流以及参与业绩电话会议后，更确信其肿瘤学业务正处于快速上升轨道，去年第四季业绩表现向好，收入按年增长约35%，主要来自于泽布替尼销售势头强劲，以及产品管线研发进度迅速的带动，目前预测若2025年公司研发管线多个项目更新研究进展，可降低临床风险及提升价值，将动股价上升，预计市场普遍预期将向上修正。
摩通认为百济神州正处于一个关键转折点，预测今年可录得美国通用会计原准则下的经营利润，除现有研发管线外，已获批产品亦可提供估值支持，给予“增持”评级，目标价从234元上调至311元。(gc/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-28 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.